Why is pharmacogenetics important?
When initiating drug therapy to treat a particular condition, healthcare practitioners typically prescribe one of several appropriate drugs. Dosages and timing of drugs are usually based upon the anticipated rate of metabolism and clearance from the body in the average person. They prescribe a "standard" dose based on factors such as weight, sex, and age. Clinically, however, each person responds uniquely to treatment and healthcare practitioners must make adjustments. For example, the healthcare practitioner may adjust the drug dose or switch to a different therapy, depending on whether the person's condition is responding to the medication and whether the individual is experiencing unpleasant or dangerous side effects. Sometimes a person may find that a treatment that has been working well suddenly causes symptoms when that person starts taking an additional drug.
The concentrations or effects of some drugs are monitored with blood tests and the drug dosages may be increased or decreased to maintain the drug level in an established therapeutic range. Follow-up of drug concentration is called therapeutic drug monitoring. If changing the drug dose is not effective in treating or controlling the person's condition, or the person still has side effects, then the person may be given a different drug.
In contrast, pharmacogenetics offers healthcare providers the opportunity to individualize drug therapy for people based on their genetic make-up. Testing people prior to initiating drug therapy to determine their likely response to different classes of drugs is a key emerging area of testing. Such genetic information could prove useful to both the healthcare practitioner and patient when choosing current and future drug therapies and drug doses. For certain medications, pharmacogenetics is already helping healthcare providers predetermine proper therapies and dosages to have a better chance of achieving the desired therapeutic effect while reducing the likelihood of adverse effects.
Genes are the basic units of genetic material, the segments of DNA that usually code for the production of specific proteins, including the proteins known as enzymes. Each person has two copies of most genes: one copy is inherited from the person's mother and one copy is inherited from the person's father. Each gene is made up of a specific genetic code, which is a sequence of nucleotides (A, T, G, or C). For each nucleotide position in the gene, one of the four nucleotides is the predominant nucleotide in the general population. This nucleotide is usually referred to as "wild type." If an individual has a nucleotide that is different from "wild type" in one copy of his or her genes, that person is said to have a heterozygous variant. If an individual has the same variant nucleotide in both copies of his or her genes, that person is said to have a homozygous variant.
Nucleotide or genetic variants (also called polymorphisms or mutations) occur throughout the population. Some genetic variants are benigndo not produce any known negative effect or may be associated with features like height, hair color, and eye color. Other genetic variants may be known to cause specific diseases. Other variants may be associated with variable response to specific medications.
Pharmacogenetic tests look for genetic variants that are associated with variable response to specific medications. These variants occur in genes that code for drug-metabolizing enzymes, drug targets, or proteins involved in immune response. Pharmacogenetic tests have the ability to determine if a variant is heterozygous or homozygous, which can impact an individual's response or reaction to a drug.
A healthcare practitioner may test a patient's genes for certain variations that are known to be involved in variable response to a medication at any time during treatment (for example, prior to treatment, during initial phase of treatment, or later in the treatment). The results of the testing may be combined with the individual's clinical information, including age, weight, health and other drugs that they are taking, to help tailor therapy. Sometimes, the healthcare practitioner may use this information to adjust the medication dose or sometimes to choose a different drug. Pharmacogenetic testing is intended to give the healthcare practitioner additional information but may not replace the need for therapeutic drug monitoring.
Pharmacogenetic testing for a specific gene is only performed once since a person's genetic makeup does not change over time. Depending on the medication, a single gene may be ordered or multiple genes may be ordered. An example of a medication for which multiple genes are usually evaluated is warfarin, which can be affected by genetic variation in CYP2C9 and VKORC1.
Testing may be ordered prior to starting specific drug therapies or if a person who has started taking a drug is experiencing side effects or having trouble establishing and/or maintaining a stable dose. Sometimes a person may not experience such issues until other medications that affect the metabolism or action of the drug in question are added or discontinued.
Pharmacogenetic testing is available for a relatively limited number of drugs. Some tests may only be applicable to specific ethnic groups. The following are examples of some drugs for which pharmacogenetic tests are available:
Currently they are only indicated if a person is going to take, or is taking, a drug that has an accepted pharmacogenetic test associated with it.
No. The FDA may recommend this testing, as in the case of irinotecan, but it is not required.
Your genetic make-up does not change over time. You may, however, have other pharmacogenetic tests performed if you take a different drug with a different associated pharmacogenetic test.
No. Since there are other factors that affect drug levels besides your genetics, therapeutic drug monitoring may still be necessary.
A blood sample is obtained by inserting a needle into a vein in the arm. Saliva samples and buccal swabs, collected by brushing the inner side of the cheek with a swab, can also be used.
Pharmacogenetic tests are performed to evaluate a person's potential response to a drug therapy. Most genetic tests have been developed to help diagnose or predict the development of a genetic disease, for forensic medicine purposes, and in establishing parentage. Another common use of genetic testing is to detect the genetic material (DNA or RNA) of bacteria and viruses to help diagnose an infection. (Read the article The Universe of Genetic Testing for more information.)
You may be monitored differently depending on the results of the test, especially when starting the medication, changing the dose, or when adding or discontinuing another medication.
This is a question to discuss with your healthcare provider and your family members. In some cases it may be useful; in others it may only be relevant if they are going to be taking the same drug or a drug in the same class. Pharmacogenetic test results are useful information for a family member to share with the healthcare practitioner along with the family's medical history.
You and your healthcare provider should consider the condition that you have, your history of drug-related side effects and/or adverse drug reactions, the drug therapies that are available, and the uses the test is intended for. Pharmacogenetic tests are not meant to stand alone but are meant to be used in conjunction with your other clinical findings.
Pharmacogenetic testing is available for a relatively limited number of medications. Pharmacogenetics tests are generally not widely used and not all insurers will cover their cost. Individuals should consult with their healthcare practitioners about these issues.
Pharmacogenetic tests are intended to provide the healthcare practitioner and patient with additional information when selecting drug treatments and dosages. For a better understanding, patients may want to consult with a genetic counselor prior to and after having a pharmacogenetic test performed. Genetic counseling and informed consent are recommended for all genetic testing.
To learn more about the role of pharmacogenetics in personalized medicine, visit the Personalized Medicine Coalition website.
The rest is here:
Pharmacogenetic Tests | LabCorp
- Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer [Last Updated On: August 17th, 2024] [Originally Added On: May 3rd, 2010]
- A new mouse mutant of the Cdh23 gene with early-onset hearing loss facilitates evaluation of otoprotection drugs [Last Updated On: August 17th, 2024] [Originally Added On: August 2nd, 2010]
- Pharmacogenomics [Last Updated On: August 17th, 2024] [Originally Added On: October 10th, 2011]
- Drug Firms Want More Access to Genetic Specimens - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 14th, 2011]
- India joins genome club -Genomics in India - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 14th, 2011]
- Classic: Weinshilboum: Inherited Variations in Drug and Neurotransmitter Metabolism 1981 - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 14th, 2011]
- Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict... - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 24th, 2011]
- Antidepressant Use Increases Significantly - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 28th, 2011]
- Kelan G. Tantisira, MD, MPH - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 31st, 2011]
- Human Security Thesis, personalized medicine, pharmacogenomics, Pharmacogenomics - Introduction - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 8th, 2011]
- Pamela Sklar: 2011 Allen Institute for Brain Science Symposium - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 8th, 2011]
- Pharmacy Doctor Oct 2011 A #1.wmv - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 13th, 2011]
- R. Stephanie Huang, PhD: The Role of Pharmacogenomics and Anticancer Drugs - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 19th, 2011]
- Individualized Molecular Testing for Personalized Medicine - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 21st, 2011]
- Where Science Meets Faith: Anticipating the Future - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 28th, 2011]
- Pharmacogenomics of psychotropic drugs - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 6th, 2011]
- 2008 IPIT Awards Seminar: Hans Hogerzeil - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 7th, 2011]
- Asuragen CLIA Pharmacogenomic Services - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 8th, 2011]
- Pilot Demonstration Projects Group 4: Pharmacogenomics - Alan Shuldiner - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 16th, 2011]
- Pharmacogenomics - Howard McLeod - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 17th, 2011]
- Clinical Implementation of Psychiatric Pharmacogenomics - David Mrazek - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 10th, 2012]
- PROMISE - Bionexus Partnership Launching montage - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 16th, 2012]
- Dr. William Figg: Handling Pharmacogenomic Information - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 19th, 2012]
- Using Payer Data to Analyze Impact of Pharmacogenomic Approaches - Robert Epstein - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 22nd, 2012]
- Dr. Russ Altman on Pharmacogenomics - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 26th, 2012]
- AssureRx Health Secures $8M Financing with Silicon Valley Bank to Support Growth [Last Updated On: August 17th, 2024] [Originally Added On: January 31st, 2012]
- BSc Biomedical Sciences courses at Brunel University - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 1st, 2012]
- Companion Diagnostics Market to Explode as Personalized Medicine Market Catapults to $42 Billion by 2015 [Last Updated On: August 17th, 2024] [Originally Added On: February 3rd, 2012]
- Gaming Wins Big at National Science Foundation's Visualization Challenge [Last Updated On: August 17th, 2024] [Originally Added On: February 14th, 2012]
- SBCE to organise international meet on Molecular Medicine [Last Updated On: August 17th, 2024] [Originally Added On: February 15th, 2012]
- FDA Evaluating MolecularHealth's MASE for Analyzing Post-Market Drug Safety [Last Updated On: August 17th, 2024] [Originally Added On: February 15th, 2012]
- Genome BC Funds $9.8M Project to Identify Subgroups in Medulloblastoma for Personalized Treatment [Last Updated On: August 17th, 2024] [Originally Added On: February 15th, 2012]
- Future US Nucleic Acid Testing Market Outlook [Last Updated On: August 17th, 2024] [Originally Added On: February 16th, 2012]
- China Clears Its First Microarray Platform for in Vitro Diagnostics to Accelerate Personalized Medicine [Last Updated On: August 17th, 2024] [Originally Added On: February 16th, 2012]
- ACLA Says Cuts in Medicare Lab Payments Could Hurt Nascent Personalized Dx Segment [Last Updated On: August 17th, 2024] [Originally Added On: February 20th, 2012]
- OncTerm- Pharmacogenomics - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 21st, 2012]
- A Negative Vote for Vivus Obesity Drug, Says 'FDA Panel Whisperer' [Last Updated On: August 17th, 2024] [Originally Added On: February 22nd, 2012]
- International meet on molecular medicine begins at SBCE [Last Updated On: August 17th, 2024] [Originally Added On: February 24th, 2012]
- Demonstrating Cost Effectiveness of Clinical NGS is Key to Payor Reimbursement, Hospital Uptake [Last Updated On: August 17th, 2024] [Originally Added On: February 24th, 2012]
- Darien High Schoolers fare well at science fair [Last Updated On: August 17th, 2024] [Originally Added On: February 27th, 2012]
- US Hematology & Flow Cytometry Market Future Discussed in New Report Published at MarketPublishers.com [Last Updated On: August 17th, 2024] [Originally Added On: February 29th, 2012]
- ACM Global Central Lab Launches Workshop Series to Share Expert Insights on Navigating Global Clinical Trials with a ... [Last Updated On: August 17th, 2024] [Originally Added On: February 29th, 2012]
- Fitch: Drug Makers Continue to Face Challenges at the Beginning of the Drug Channel [Last Updated On: August 17th, 2024] [Originally Added On: February 29th, 2012]
- Will PCORI's Patient-Centered Comparative Effectiveness Research Track with Personalized Rx? [Last Updated On: August 17th, 2024] [Originally Added On: March 3rd, 2012]
- Generex to Meet with FDA about AE37 HER2 Peptide Vaccine; Companion Dx Path Still Unclear [Last Updated On: August 17th, 2024] [Originally Added On: March 6th, 2012]
- Vermillion's OVA1 Test Assigned Category 1 CPT Code; Stock Jumps [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- Transgenomic Reports Fiscal Year 2011 Financial Results [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- Transgenomic's Q4 Revenues Increase 69 Percent [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- Research and Markets: Molecular Diagnostics: Market Segmentation and Opportunities - Emphasis on NGS and Its Emerging ... [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- AMA Approves Vermillion MAAA Category 1 Code for OVA1; Will it Improve Reimbursement? [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- USPSTF Updating BRCA Testing Recommendations for Asymptomatic Women; Accepting Public Input [Last Updated On: August 17th, 2024] [Originally Added On: March 8th, 2012]
- Global Biochips Market to Reach US$4.6 Billion by 2017, According to New Report by Global Industry Analysts, Inc. [Last Updated On: August 17th, 2024] [Originally Added On: March 10th, 2012]
- WSU venturing into pharmacogenomics - Tue, 13 Mar 2012 PST [Last Updated On: August 17th, 2024] [Originally Added On: March 13th, 2012]
- Research and Markets: Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice (6th ... [Last Updated On: August 17th, 2024] [Originally Added On: March 14th, 2012]
- With MDx Usage and Costs on the Rise, UnitedHealthCare Urges Reimbursement Reform [Last Updated On: August 17th, 2024] [Originally Added On: March 14th, 2012]
- Bioinformatics Market Outlook to 2015 [Last Updated On: August 17th, 2024] [Originally Added On: March 15th, 2012]
- WSU recruits geneticists in new research venture [Last Updated On: August 17th, 2024] [Originally Added On: March 15th, 2012]
- Pharmacogenomics - Video [Last Updated On: August 17th, 2024] [Originally Added On: March 15th, 2012]
- Free Book Download - Psychiatric Pharmacogenomics - Video [Last Updated On: August 17th, 2024] [Originally Added On: March 16th, 2012]
- PanGenX Takes Semantic-based Approach to Data Integration, Analytics for Personalized Medicine [Last Updated On: August 17th, 2024] [Originally Added On: March 17th, 2012]
- Research and Markets: Bioinformatics Market Outlook to 2015 [Last Updated On: August 17th, 2024] [Originally Added On: March 21st, 2012]
- Quest Launches MDx that May Predict Kidney Transplant Rejection Earlier than Current Methods [Last Updated On: August 17th, 2024] [Originally Added On: March 21st, 2012]
- EMERGE Network Launches Publicly Available Database of Phenotype Identification Algorithms [Last Updated On: August 17th, 2024] [Originally Added On: March 23rd, 2012]
- Prospective Outcomes Trial Shows Agendia's MammaPrint Safely Reduces Chemo Use in Low-Risk Patients [Last Updated On: August 17th, 2024] [Originally Added On: March 26th, 2012]
- Abbott Challenges 'Incorrect Assumptions' in Cost-Effectiveness Study of Xalkori PGx Testing [Last Updated On: August 17th, 2024] [Originally Added On: March 26th, 2012]
- Genoptix Says NGS Melanoma Test Will Not Be Used to Place Patients in Trials for Parent Novartis [Last Updated On: August 17th, 2024] [Originally Added On: March 28th, 2012]
- St. Jude's Evans Receives Pharmacists Assn. Award [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- Perkins Chain Hires New CEO [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- PGx Highlights from American College of Cardiology Annual Meeting [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- Collecting Cancer Data [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- Study: Higher Plavix Dose Doesn't Improve Response for CYP2C19*2 Carriers; Effient May Be Best Option [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- UNC Analysis Finds Beta1-AR Alleles Impact Survival in Patients Treated with Beta-Blockers [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- Q&A: GE Healthcare's Mark Dente on the Challenges of Integrating Genomics Data with EMRs [Last Updated On: August 17th, 2024] [Originally Added On: March 31st, 2012]
- Eastday-Neurosurgeon, geneticist take top prizes in science [Last Updated On: August 17th, 2024] [Originally Added On: March 31st, 2012]
- A New 'Omics Emerges [Last Updated On: August 17th, 2024] [Originally Added On: April 2nd, 2012]
- Up to the Task [Last Updated On: August 17th, 2024] [Originally Added On: April 2nd, 2012]
- NHGRI Plans to Fund More Clinical Sequencing Projects [Last Updated On: August 17th, 2024] [Originally Added On: April 7th, 2012]
- Doctor’s role is key to cancer fight [Last Updated On: August 17th, 2024] [Originally Added On: April 16th, 2012]
- People in the News: Josh LaBaer in as New President of US HUPO and More [Last Updated On: August 17th, 2024] [Originally Added On: April 22nd, 2012]
- Convey, CLC Bio to Provide Combined Software, Hardware NGS Data-Analysis Solution [Last Updated On: August 17th, 2024] [Originally Added On: April 22nd, 2012]